Videos,
Caitlin Sheetz Shares Insight on Evaluating the Impact of 2025 Healthcare Policies
ADVI Health’s Caitlin Sheetz, MPH, head of strategic analytics, value and economics (SAVEs), shared insight on the main challenges that the SAVEs team experienced in 2024, heavily focusing around evidence generation, as well as what the team expects to see in 2025. This past year, the team helped clients determine data sets, statistical methods to employ, and how to present the information for the intended audience in order to best demonstrate our the value of their products and ensure coverage and access to patients.
In 2025, Caitlin shares that the team will be prepared to leverage their expansive data assets, along with their strategic analytic expertise to help clients evaluate the impact of the new healthcare policies considering the new administration, navigate drug products launching and reimbursement dynamics, and generate evidence to demonstrate value to their products.
Learn more about ADVI’s Strategic Analytics, Value and Economics (SAVEs) expertise.
ADVI Health’s Caitlin Sheetz, head of Strategic Analytics, Value and Economics (SAVEs), reflects on several challenges the team experienced throughout 2024, heavily centered around evidence generation, and what is expected in 2025.
Panelists
Head of SAVEs
Caitlin leads ADVI’s strategic analytics, value and economics (SAVEs) team, assisting clients by using data to create comprehensive analytic models that they can use to evaluate the implications of health policies.
Full Transcript
Caitlin Sheetz: One of the main challenges that we engaged with our clients on in 2024 was around evidence generation. Helping to determine what data set to use, which statistical methods to employ, and how best to present the information for the intended audience. Whether it was preparing for IRA drug price negotiations, advocating for separate reimbursement under Medicare’s prospective payment systems, or publishing peer reviewed manuscripts, ADVI partnered with our clients to help demonstrate value for their products, and ensure coverage and access to patients.
As we head into 2025, we expect to see changes to healthcare policies with the new administration. ADVI will be ready and well positioned to leverage our expansive data assets, along with our strategic analytic expertise to help clients evaluate impact of new policies, navigate drug products launching and reimbursement dynamics, and generate evidence to demonstrate value to their products.
As ADVI continues to grow, we are more excited to bring a more comprehensive set of the HEOR services to our clients. With our recent acquisition of PHAR, ADVI now has extensive primary and secondary research capabilities, spanning Delphi panels, registry and chart reviews, as well as claims and EHR analytics. We have a team of researchers that bring clinical and statistical expertise to use data to answer complex questions. We look forward to discussing these new capabilities with you. Please get in touch.
Learn More
Stay ahead of the curve this year. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.